PMV PHARMACEUTICALS, INC. Earnings Per Share, Basic and Diluted
PMV PHARMACEUTICALS, INC. (PMVP) reported Earnings Per Share, Basic and Diluted of -$0.38 per share for the 3-month period ending 2022-06-30, per its 10-Q filed 2022-08-09.
Discontinued › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasicAndDiluted · last filed 2022-08-09
- PMV PHARMACEUTICALS, INC. earnings per share, basic and diluted for the quarter ending 2022-06-30 was -$0.38.
- PMV PHARMACEUTICALS, INC. earnings per share, basic and diluted for the quarter ending 2022-03-31 was -$0.41.
- PMV PHARMACEUTICALS, INC. earnings per share, basic and diluted for the quarter ending 2021-12-31 was -$0.40.
- PMV PHARMACEUTICALS, INC. earnings per share, basic and diluted for the quarter ending 2021-09-30 was -$0.33.
- PMV PHARMACEUTICALS, INC. earnings per share, basic and diluted for fiscal 2021 was -$1.28.
- PMV PHARMACEUTICALS, INC. earnings per share, basic and diluted for fiscal 2020 was -$2.40.
- PMV PHARMACEUTICALS, INC. earnings per share, basic and diluted for fiscal 2019 was -$8.35.
- PMV PHARMACEUTICALS, INC. earnings per share, basic and diluted for fiscal 2018 was -$5.82.
| Period end | Earnings Per Share, Basic and Diluted 3 month | Earnings Per Share, Basic and Diluted 6 month | Earnings Per Share, Basic and Diluted 9 month | Earnings Per Share, Basic and Diluted 12 month |
|---|---|---|---|---|
| 2022-06-30 | -$0.38 10-Q · filed 2022-08-09 | -$0.79 10-Q · filed 2022-08-09 | -$1.19 derived: net income ÷ weighted average shares · filed 2024-02-29 | -$1.52 derived: net income ÷ weighted average shares · filed 2024-02-29 |
| 2022-03-31 | -$0.41 10-Q · filed 2022-05-10 | -$0.81 derived: net income ÷ weighted average shares · filed 2024-02-29 | -$1.14 derived: net income ÷ weighted average shares · filed 2024-02-29 | -$1.43 derived: net income ÷ weighted average shares · filed 2024-02-29 |
| 2021-12-31 | -$0.40 derived: net income ÷ weighted average shares · filed 2024-02-29 | -$0.74 derived: net income ÷ weighted average shares · filed 2024-02-29 | -$1.02 derived: net income ÷ weighted average shares · filed 2024-02-29 | -$1.28 10-K · filed 2022-03-01 |
| 2021-09-30 | -$0.33 10-Q · filed 2021-11-12 | -$0.62 derived: net income ÷ weighted average shares · filed 2022-11-08 | -$0.88 10-Q · filed 2021-11-12 | -$1.11 derived: net income ÷ weighted average shares · filed 2023-03-01 |
| 2021-06-30 | -$0.29 10-Q · filed 2022-08-09 | -$0.54 10-Q · filed 2022-08-09 | -$0.78 derived: net income ÷ weighted average shares · filed 2023-03-01 | -$1.24 derived: net income ÷ weighted average shares · filed 2023-03-01 |
| 2021-03-31 | -$0.26 10-Q · filed 2022-05-10 | -$0.49 derived: net income ÷ weighted average shares · filed 2023-03-01 | -$0.96 derived: net income ÷ weighted average shares · filed 2023-03-01 | -$1.56 derived: net income ÷ weighted average shares · filed 2023-03-01 |
| 2020-12-31 | -$0.23 derived: net income ÷ weighted average shares · filed 2023-03-01 | -$0.75 derived: net income ÷ weighted average shares · filed 2023-03-01 | -$1.50 derived: net income ÷ weighted average shares · filed 2023-03-01 | -$2.40 10-K · filed 2022-03-01 |
| 2020-09-30 | -$1.46 10-Q · filed 2021-11-12 | -$3.69 derived: net income ÷ weighted average shares · filed 2021-11-12 | -$5.93 10-Q · filed 2021-11-12 | -$8.19 derived: net income ÷ weighted average shares · filed 2022-03-01 |
| 2020-06-30 | -$2.62 10-Q · filed 2021-08-13 | -$5.00 10-Q · filed 2021-08-13 | -$7.31 derived: net income ÷ weighted average shares · filed 2022-03-01 | -$9.34 derived: net income ÷ weighted average shares · filed 2022-03-01 |
| 2020-03-31 | -$2.38 10-Q · filed 2021-05-14 | -$4.69 derived: net income ÷ weighted average shares · filed 2022-03-01 | -$6.72 derived: net income ÷ weighted average shares · filed 2022-03-01 | |
| 2019-12-31 | -$2.31 derived: net income ÷ weighted average shares · filed 2022-03-01 | -$4.34 derived: net income ÷ weighted average shares · filed 2022-03-01 | -$8.35 10-K · filed 2022-03-01 | |
| 2019-09-30 | -$2.03 10-Q · filed 2020-11-13 | -$6.04 10-Q · filed 2020-11-13 | ||
| 2018-12-31 | -$5.82 10-K · filed 2021-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 | |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |